Cynthia Hinck

Cynthia Hinck

Auto-generated profile, based on publicly available information

Cynthia Hinck

Department of Structural Biology, University of Pittsburgh, Pittsburgh, PA, 15261 U.S.A.

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
KDKristin DePeaux
Kristin DePeaux
DRDayana B. Rivadeneira
Dayana B. Rivadeneira
KLKonstantinos Lontos
Konstantinos Lontos
VDVictoria G. Dean
Victoria G. Dean
WGWilliam G. Gunn
William G. Gunn
GDGreg M. Delgoffe
Greg M. Delgoffe
While checkpoint blockade immunotherapies have widespread success, they rely on a responsive immune infiltrate; as such, treatments enhancing immune infiltration and preventing immunosuppression are of critical need. We previously generated αPD-1 resistant variants of the murine HNSCC model MEER. While entirely αPD-1 resistant, these tumors regress after single dose of oncolytic vaccinia virus (VV). We then generated a VV-resistant MEER line to dissect the immunologic features of sensitive and resistant tumors. While treatment of both tumor types induced immune infiltration and IFNγ, we found a defining feature of resistance was elevation of immunosuppressive cytokines like TGFβ, which blunted IFNγ signaling, especially in regulatory T cells. We engineered VV to express a genetically encoded TGFβRII inhibitor. Inhibitor-expressing VV produced regressions in resistant tumor models and showed impressive synergy with checkpoint blockade. Importantly, tumor-specific, viral delivery of TGFβ inhibition had no toxicities associated with systemic TGFβ/TGFβR inhibition. Our data suggest that aside from stimulating immune infiltration, oncolytic viruses are attractive means to deliver agents to limit immunosuppression in cancer.

17 December 2021 in Science Advances
Verified
Journal Article
Open access
EBEmilie Brûlé
Emilie Brûlé
YWYing Wang
Ying Wang
YLYining Li
Yining Li
YLYeu-Farn Lin
Yeu-Farn Lin
XZXiang Zhou
Xiang Zhou
DBDaniel J. Bernard
Daniel J. Bernard
Discovery of a novel pituitary protein suggests a new means to enhance fertility.

12 October 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
ISIsaac Sappington
Isaac Sappington
MTMartin Toul
Martin Toul
DLDavid S. Lee
David S. Lee
SRStephanie A. Robinson
Stephanie A. Robinson
IGInna Goreshnik
Inna Goreshnik
DBDavid Baker
David Baker
Despite recent advances in the computational design of protein binders, designing proteins that bind with high affinity to polar protein targets remains an outstanding problem. Here we show that RFdiffusion can be conditioned to efficiently generate protein scaffolds that form geometrically matched extended beta-sheets with target protein edge beta-strands in which polar groups on the target are nearly perfectly complemented with hydrogen bonding groups on the design. We use this approach to design binders against a set of therapeutically relevant polar targets (KIT, PDGFRɑ, ALK-2, ALK-3, FCRL5, and NRP1) and find that beta-strand-targeted design yields higher affinities and success rates than unconditioned RFdiffusion. All by all binding experiments show that the designs have affinities ranging from 137 pM to mid nM for their targets and essentially no off target binding despite the sharing of beta-strand interactions, likely reflecting the precise customization of interacting beta-strand geometry and additional designed binder-target interactions. A co-crystal structure of one such design in complex with the KIT receptor is nearly identical to the computational design model confirming the accuracy of the design approach. The ability to robustly generate binders displaying high affinity and specificity to polar interaction surfaces with exposed beta-strands considerably increases the range and capabilities of computational binder design.

15 January 2021 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
TCTeresa L. Capasso
Teresa L. Capasso
STSara M. Trucco
Sara M. Trucco
MHMorgan Hindes
Morgan Hindes
TSTristin Schwartze
Tristin Schwartze
JBJamie L. Bloch
Jamie L. Bloch
Beth RomanBeth Roman
Beth Roman

1 August 2025 in Cancer Research Communications
Verified
Journal Article
Open access
JDJessica D. Daley
Jessica D. Daley
EMElina Mukherjee
Elina Mukherjee
DFDavid Ferraro
David Ferraro
ATA. Carolina Tufino
A. Carolina Tufino
NBNathanael Glen Bailey
Nathanael Glen Bailey
KBKelly M. Bailey
Kelly M. Bailey
Ewing sarcoma is an aggressive cancer diagnosed in adolescents and young adults. Inhibition of TGFβ is being tested in limited clinical trials for relapsed Ewing sarcoma. TGFβ is an immunosuppressive cytokine that exists in latent and active states. The functional impact of TGFβ inhibition on the Ewing tumor microenvironment (TME) and on Ewing tumor behavior remains largely unknown. In this study, we use single-cell RNA sequencing analysis of human Ewing tumors to demonstrate that immune cells are the largest contributors of TGFB1 expression in the human Ewing TME. We utilize a humanized mouse model of Ewing sarcoma to demonstrate that TME signatures in these models differ significantly from Ewing sarcoma tumors developed in immunodeficient mice. Using this humanized model, we investigate the effect of TGFβ inhibition on the Ewing sarcoma TME during radiotherapy, a treatment that is commonly used to treat unresectable, metastatic, and relapsed/refractory Ewing sarcoma that is known to enhance TGFβ activation in multiple cancers. Utilizing a trivalent ligand TGFβ trap to inhibit TGFβ, we demonstrate that in combination with radiotherapy, TGFβ inhibition both increases Ewing sarcoma immune cell infiltration and decreases lung metastatic burden in vivo. These data demonstrate the value of immunocompetent models to address immune-biological preclinical questions in Ewing sarcoma and demonstrate that TGFβ inhibition during radiotherapy is a promising strategy to enhance antitumor immune response and improve treatment efficacy for metastatic Ewing sarcoma. Significance: This work demonstrates the importance of disrupting immunosuppression during radiotherapy to reduce lung metastatic potential in Ewing sarcoma. Humanized mouse models of Ewing sarcoma are also established as an immunocompetent preclinical tool to ask therapeutic questions about the Ewing TME.

11 July 2020 in medRxiv
Verified
Preprint
Open access
TCTeresa L. Capasso
Teresa L. Capasso
STSara M. Trucco
Sara M. Trucco
MHMorgan Hindes
Morgan Hindes
TSTristin Schwartze
Tristin Schwartze
JBJamie L. Bloch
Jamie L. Bloch
Beth RomanBeth Roman
Beth Roman
In children with single ventricle physiology, the Glenn procedure is performed to redirect venous return from the superior vena cava directly to the pulmonary arteries and route venous return from the inferior vena cava exclusively to the systemic circulation. Although this surgery successfully palliates the hemodynamic stress experienced by the single ventricle, patients frequently develop pulmonary arteriovenous malformations (PAVMs). Interestingly, PAVMs may regress upon rerouting of hepatic venous effluent to the pulmonary vasculature, suggesting the presence of a circulating “hepatic factor” that is required to prevent PAVMs. Here, we test the hypothesis that hepatic factor is bone morphogenetic protein 9 (BMP9) and/or BMP10. These circulating ligands are produced by the liver and activate endothelial endoglin (ENG)/ALK1 signaling, and mutations in ENG and ALK1 cause hereditary hemorrhagic telangiectasia, a genetic disease associated with AVM development. However, we found no within-subject variation in BMP9, BMP10, or BMP9/10 plasma concentrations when sampled from five cardiovascular sites, failing to support the idea that the Glenn would limit access of these ligands to the lung vasculature. Unexpectedly, however, we found a significant decrease in all three ligand concentrations in Glenn cases versus controls. Our findings suggest that BMP9/BMP10/ENG/ALK1 signaling may be decreased in the Glenn vasculature but fail to implicate these ligands as hepatic factor.